At a Glance
- Sanofi has completed the acquisition of Dynavax Technologies
- Deal adds HEPLISAV-B, a two-dose adult hepatitis B vaccine
- Includes shingles vaccine candidate Z-1018 and pipeline assets
- Dynavax shareholders to receive $15.50 per share in cash
Written By: Pharmacally Medical News Desk
Sanofi has completed its acquisition of Dynavax Technologies Corporation, formally bringing the vaccine developer and its portfolio into Sanofi’s expanding vaccines business.
The transaction adds Dynavax’s adult hepatitis B vaccine, HEPLISAV-B, to Sanofi’s commercial portfolio. The vaccine is differentiated by its two-dose regimen administered over one month, offering a shorter schedule compared with traditional multi-dose hepatitis B vaccines. The acquisition also includes Dynavax’s shingles vaccine candidate (Z-1018), currently in Phase 1/2 clinical development, along with additional pipeline programs.
Sanofi said the deal strengthens its position in adult immunization by combining Dynavax’s vaccine assets with Sanofi’s global scale, commercial reach, and development capabilities. The strategic move aligns with Sanofi’s broader focus on expanding its vaccines franchise, particularly in areas of unmet need and improved vaccination convenience.
The acquisition was completed following the successful expiration of Sanofi’s tender offer for all outstanding shares of Dynavax common stock. The offer expired shortly after 11:59 p.m. EST on February 9, 2026, with all required conditions satisfied. On February 10, Sanofi accepted for payment and will promptly pay for all validly tendered shares.
Sanofi finalized the transaction through a merger under Section 251(h) of Delaware law, resulting in Dynavax becoming an indirect, wholly owned subsidiary of Sanofi. Shareholders whose shares were not tendered will receive the same consideration of $15.50 per share in cash, subject to applicable withholding taxes.
Following completion of the merger, Dynavax common stock will cease trading on the NASDAQ Global Select Stock Market.
This development follows Sanofi’s earlier announcement of its intention to acquire Dynavax, underscoring the company’s continued investment in strengthening its adult vaccine portfolio.
References
Press Release: Sanofi completes the acquisition of Dynavax, 10 February 2026, Press Release: Sanofi completes the acquisition of Dynavax
Sanofi to Acquire Dynavax, Strengthening Adult Vaccine Portfolio with HEPLISAV-B and Shingles Candidate, 24 December 2025, https://pharmacally.com/sanofi-to-acquire-dynavax-strengthening-adult-vaccine-portfolio-with-heplisav-b-and-shingles-candidate/